- Home
- CWK vs EWTX Comparison
CWK vs EWTX Comparison
Compare CWK & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWK | EWTX |
|---|---|---|
| Founded | 1784 | 2017 |
| Country | United States | United States |
| Employees | 53000 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.7B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CWK | EWTX |
|---|---|---|
| Price | $13.42 | $46.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $17.64 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 2.3M | 1.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,288,200,000.00 | N/A |
| Revenue This Year | $6.87 | N/A |
| Revenue Next Year | $5.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.91 | N/A |
| 52 Week Low | $10.94 | $12.31 |
| 52 Week High | $17.40 | $43.93 |
Technical Indicators
Market Signals| Indicator | CWK | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 72.74 |
| Support Level | $11.78 | $28.27 |
| Resistance Level | $14.22 | N/A |
| Average True Range (ATR) | 0.47 | 2.50 |
| MACD | 0.05 | 0.52 |
| Stochastic Oscillator | 50.34 | 97.31 |
Price Performance
Historical ComparisonAbout CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world and is headquartered in Chicago. The firm provides a broad suite of real estate-related services to owners, tenants, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such as valuation, project management, and facilities management.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.